Patents Assigned to Pfizer
  • Process for preparing phenoxyphenylsulfonyl halides
    Patent number: 6118016
    Abstract: A process for preparing phenoxyphenylsulfonyl halides, which are useful intermediates for the preparation of matrix metalloproteinase inhibitors.
    Type: Grant
    Filed: April 7, 1999
    Date of Patent: September 12, 2000
    Assignee: Pfizer Inc.
    Inventor: Joel M. Hawkins
  • Benzopyran and benzo-fused compounds, their preparation and their use as leukotriene B.sub.4 (LTB.sub.4 ) antagonists
    Patent number: 6117874
    Abstract: This invention relates to novel benzopyran and other benzo-fused leukotriene B.sub.4 (LTB.sub.4) antagonists and the pharmaceutically acceptable salts thereof, to pharmaceutical compositions containing such compounds, and to a method of using such compounds as LTB.sub.4 antagonists. The compounds of this invention inhibit the action of LTB.sub.4 and are therefore useful in the treatment of LTB.sub.4 induced illnesses such as inflammatory disorders including rheumatoid arthritis, osteoarthritis, inflammatory bowel disease, psoriasis and other skin disorders such as eczema, erythema, pruritus and acne, stroke and other forms of reperfusion injury, graft rejection, autoimmune diseases, asthma, and other conditions where marked neutrophil infiltration occurs.
    Type: Grant
    Filed: February 1, 1999
    Date of Patent: September 12, 2000
    Assignee: Pfizer Inc.
    Inventors: Mark Anthony Dombroski, Kevin Koch, Anthony Daniel Piscopio
  • Process for alkylating hindered sulfonamides useful in the production of matrix metalloproteinase inhibitors
    Patent number: 6114568
    Abstract: The present invention relates to a process for alkylating hindered sulfonamides useful as intermediates in the preparation of matrix metalloproteinase inhibitors.
    Type: Grant
    Filed: April 9, 1999
    Date of Patent: September 5, 2000
    Assignee: Pfizer Inc.
    Inventors: Brian Michael Andresen, Phillip Dietrich Hammen, Joel Michael Hawkins
  • Method of treating atherosclerosis
    Patent number: 6114395
    Abstract: A method of treating atherosclerosis, independent of lipid lowering, in mammals, including humans, in need of treatment by inhibiting progression of an atherogenic lesion or by stabilizing plaque. Such lesion progression inhibition or plaque stabilization is achieved by directly inhibiting chemokine expression leading to excessive inflammatory cell recruitment by administering a therapeutically effective amount of a compound of formula I.
    Type: Grant
    Filed: October 21, 1997
    Date of Patent: September 5, 2000
    Assignee: Pfizer Inc.
    Inventor: Robert J. Aiello
  • Process for preparing quinolone and naphthyridone carboxylic acids
    Patent number: 6114531
    Abstract: Antibacterial quinolone carboxylic acids and naphthyridone carboxylic acids, having an external amino group attached to their 7-substituent are prepared without the use, and subsequent removal, of blocking groups on the external amino group. In a preferred embodiment, the naphthyridone carboxylic acid is the antibiotic trovafloxacin.
    Type: Grant
    Filed: June 2, 1999
    Date of Patent: September 5, 2000
    Assignee: Pfizer Inc.
    Inventor: Timothy Norris
  • Psoriasis treatment
    Patent number: 6113893
    Abstract: The present invention is directed to a topical composition for the treatment of psoriasis. The composition comprises a film forming agent, a plasticizer, an aqueous alcoholic solution and an amount of alkali effective to prevent the gellation of the film forming agent.
    Type: Grant
    Filed: July 1, 1998
    Date of Patent: September 5, 2000
    Assignee: Pfizer Inc.
    Inventors: Debbie L. Burnett, Victor M. Wong, Darius D. Dubash, Athanasios S. Ladas
  • 5-oxo-pyrrolidine-2-carboxylic acid hydroxamide derivatives
    Patent number: 6114361
    Abstract: The present invention relates to a compound of the formula ##STR1## wherein R.sup.1, R.sup.2, R.sup.3 are as defined above, to pharmaceutical compositions and methods of treatment.
    Type: Grant
    Filed: October 29, 1999
    Date of Patent: September 5, 2000
    Assignee: Pfizer Inc.
    Inventors: Ralph P. Robinson, Ellen R. Laird
  • Isoxazoline compounds as inhibitors of TNF release
    Patent number: 6114367
    Abstract: This invention relates to isoxazoline compounds which are inhibitors of tumor necrosis factor (TNF). The isoxazoline compounds are useful for inhibiting TNF in a mammal in need thereof and in the treatment or alleviation of inflammatory conditions or disease, including but not limited to rheumatoid arthritis, osteoarthritis, asthma, bronchitis, chronic obstructive airways disease, psoriasis, allergic rhinitis, dermatitis and inflammatory bowel disease, sepsis, septic shock, tuberculosis, graft versus host disease and cachexia associated with AIDS or cancer. This invention also relates to pharmaceutical compositions useful therefor comprising such compounds.
    Type: Grant
    Filed: November 6, 1998
    Date of Patent: September 5, 2000
    Assignee: Pfizer Inc
    Inventors: Victoria Lee Cohan, Edward Fox Kleinman
  • Salts of an anti-migraine indole derivative
    Patent number: 6110940
    Abstract: The present invention relates to hydrobromide salts of 3-(N-methyl-2(R)-pyrrolidinylmethyl)-5-(2-phenylsulphonylethyl)-1H-indole having the formula (I): ##STR1##
    Type: Grant
    Filed: February 2, 1997
    Date of Patent: August 29, 2000
    Assignee: Pfizer Inc.
    Inventors: Valerie Denise Harding, Ross James Macrae, Ronald James Ogilvie
  • Mesylate trihydrate salt of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihy dro-2(1H)-indol-2-one (=ziprasidone), its preparation and its use as dopamine D2 antagonist
    Patent number: 6110918
    Abstract: Mesylate Trihydrate Salt of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydr o-2(1H)-indol-2-one (=Ziprasidone), Its Preparation and Its Use as Dopamine D2 AntagonistThe invention relates to the mesylate trihydrate salt of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydr o-2(1H)-indol-2-one ("ziprasidone mesylate trihydrate"), to pharmaceutical compositions containing ziprasidone mesylate trihydrate, and to methods of administering ziprasidone mesylate trihydrate to treat psychotic diseases.
    Type: Grant
    Filed: March 2, 1999
    Date of Patent: August 29, 2000
    Assignee: Pfizer Inc
    Inventors: Frank R. Busch, Carol A. Rose
  • Pyrrolidinyl hydroxamic acid compounds and their production process
    Patent number: 6110947
    Abstract: A compound of the formula: ##STR1## and it pharmaceutically acceptable salt, wherein A is hydrogen, hydroxy or OY, where Y is a hydroxy protecting group;Ar is phenyl optionally substituted with one or more substituents selected from halo, hydroxy, C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 alkoxy, CF.sub.3, C.sub.1 -C.sub.4 alkyloxy, and carboxy-C.sub.1 -C.sub.4 alkyloxy;X is phenyl, naphthyl, biphenyl, indanyl, benzofuranyl, benzothiopheny, 1-tetralone-6-yl, C.sub.1 -C.sub.4 alkylenedioxy, pyridyl, furyl and thienyl, these groups optionally being substituted with up to three substituents selected from halo, C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 alkoxy, hydroxy, NO.sub.2, CF.sub.3 and SO.sub.2 CH.sub.3 ; andR is hydrogen, C.sub.1 -C.sub.4 alkyl or a hydroxy protecting group.
    Type: Grant
    Filed: April 29, 1999
    Date of Patent: August 29, 2000
    Assignee: Pfizer Inc.
    Inventor: Fumitaka Ito
  • Pyrrole compounds having parasiticidal properties
    Patent number: 6110958
    Abstract: Compounds of formula (I) ##STR1## wherein the substituents are as defined herein, are antiparasitic agents.
    Type: Grant
    Filed: December 1, 1999
    Date of Patent: August 29, 2000
    Assignee: Pfizer Inc.
    Inventors: Bernard Joseph Banks, Nathan Anthony Logan Chubb
  • Bicyclic hydroxamic acid derivatives
    Patent number: 6110964
    Abstract: A compound of the formula ##STR1## wherein Z and Q are as defined in the specification, to pharmaceutical compositions containing them and to their medicinal use.
    Type: Grant
    Filed: September 30, 1999
    Date of Patent: August 29, 2000
    Assignee: Pfizer Inc.
    Inventor: Ralph Pelton Robinson
  • Growth hormone secretagogues
    Patent number: 6110932
    Abstract: This invention is directed to compounds of the formula ##STR1## and the pharmaceutically-acceptable salts thereof, where the substituents are as defined in the Specification, which are growth hormone secretogogues and which increase the level of endogenous growth hormone. The compounds of this invention are useful for the treatment and prevention of osteoporosis, congestive heart failure, frailty associated with aging, obesity; accelerating bone fracture repair, attenuating protein catabolic response after a major operation, reducing cachexia and protein loss due to chronic illness, accelerating would healing, or accelerating the recovery of burn patients or patients having undergone major surgery; improving muscle strength, mobility, maintanence of skin thickness, metabolic homeostasis or renal homeostasis.
    Type: Grant
    Filed: March 1, 1999
    Date of Patent: August 29, 2000
    Assignee: Pfizer Inc.
    Inventors: Philip A Carpino, Paul A DaSilva-Jardine, Bruce A Lefker, John A Ragan
  • Processes and intermediates for preparing 3-(1-piperazinyl)-1,2-benzisothiazole
    Patent number: 6111105
    Abstract: The present invention relates to processes for the preparation of 3-(1-piperazinyl)-1,2-benzoisothiazole or its pharmaceutically acceptable salt and to novel intermediates used in the process.
    Type: Grant
    Filed: October 15, 1998
    Date of Patent: August 29, 2000
    Assignee: Pfizer, Inc.
    Inventors: Darrell E. Fox, John F. Lambert, Terry G. Sinay, Stanley W. Walinsky
  • Diazabicyclic neurokinin antagonists
    Patent number: 6110919
    Abstract: The present invention relates to diazabicyclic compounds and, specifically, to compounds of the formula ##STR1## wherein A, G, R.sup.1, R.sup.2, R.sup.3, R.sup.4.sub.1 R.sup.5, R.sup.6, and R.sup.7 are as defined in the specification. The compounds of formula I are useful in the treatment of inflammatory and central nervous system disorders, as well as other disorders.
    Type: Grant
    Filed: November 23, 1998
    Date of Patent: August 29, 2000
    Assignee: Pfizer Inc.
    Inventors: Harry R. Howard, Kevin D. Shenk
  • Loratadine for use as an antiarrhythmic
    Patent number: 6110927
    Abstract: A method of treating atrial fibrillation in mammals using loratadine.
    Type: Grant
    Filed: June 28, 1999
    Date of Patent: August 29, 2000
    Assignee: Pfizer Inc
    Inventors: Guy Buckland, Tilman Friedrich, Carol A. Satler
  • Arylsulfonylamino hydroxamic acid derivatives
    Patent number: 6107337
    Abstract: A compound of the formula ##STR1## wherein n, X, R.sup.3, R.sup.4 and Ar are as defined above, useful in the treatment of a condition selected from the group consisting of arthritis, cancer, tissue ulceration, restenosis, periodontal disease, epidermolysis bullosa, scleritis, bone resorption, loosening of artificial joint implants, atherosclerosis, multiple sclerosis, occular angiogenisis and other diseases characterized by matrix metalloproteinase activity, AIDS, sepsis, septic shock and other diseases involving the production of TNF.
    Type: Grant
    Filed: August 6, 1998
    Date of Patent: August 22, 2000
    Assignee: Pfizer Inc.
    Inventor: Ralph P. Robinson
  • Heterocyclic compounds
    Patent number: 6107306
    Abstract: This invention is directed to compounds of the formula ##STR1## and the pharmaceutically-acceptable salts thereof, where the substituents are as defined in the Specification, which are growth hormone secretogogues and which increase the level of endogenous growth hormone. The compounds of this invention are useful for the treatment and prevention of osteoporosis, congestive heart failure, frailty associated with aging, obesity; accelerating bone fracture repair, attenuating protein catabolic response after a major operation, reducing cachexia and protein loss due to chronic illness, accelerating wound healing, or accelerating the recovery of burn patients or patients having undergone major surgery; improving muscle strength, mobility, maintanence of skin thickness, metabolic homeostasis or renal homeostasis.
    Type: Grant
    Filed: March 1, 1999
    Date of Patent: August 22, 2000
    Assignee: Pfizer Inc.
    Inventors: Philip A Carpino, Paul A DaSilva-Jardine, Bruce A Lefker, John A Ragan
  • Applicator
    Patent number: D430703
    Type: Grant
    Filed: October 1, 1999
    Date of Patent: September 5, 2000
    Assignee: Pfizer Inc.
    Inventors: Stuart M. Leslie, Charles Curtiss, Chen Jiang